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S U M M A R Y
Objective: To evaluate the performance of Xpert MTB/RIF (MTB/RIF) in the county-level tuberculosis (TB)
laboratory in China.
Methods: From April 2011 to January 2012, patients with suspected multidrug-resistant tuberculosis
(MDR-TB) and non-MDR-TB were enrolled consecutively from four county-level TB laboratories. The
detection of Mycobacterium tuberculosis (MTB) by MTB/RIF was compared to detection by Lo¨wenstein–
Jensen culture. The detection of rifampin resistance was compared to detection by conventional drug-
susceptibility testing. The impact of multiple specimens on the performance of MTB/RIF was also
evaluated.
Results: A total of 2142 suspected non-MDR-TB cases and 312 suspected MDR-TB cases were enrolled.
For MTB detection in suspected non-MDR-TB cases, the sensitivity and speciﬁcity of MTB/RIF were 94.4%
and 90.2%, respectively. The sensitivity in smear-negative patients was 88.8%. For the detection of
rifampin resistance in suspected non-MDR-TB cases, the sensitivity and speciﬁcity of MTB/RIF were
87.1% and 97.9%, respectively. For the detection of rifampin resistance in suspected MDR-TB cases, the
sensitivity and speciﬁcity of MTB/RIF were 87.1% and 91.0%, respectively. Using multiple sputum
specimens had no signiﬁcant inﬂuence on the performance of MTB/RIF for MTB detection.
Conclusions: The introduction of MTB/RIF could increase the accuracy of detection of MTB and rifampin
resistance in peripheral-level TB laboratories in China. One single specimen is adequate for TB diagnosis
by MTB/RIF.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Tuberculosis (TB) remains a signiﬁcant public health problem
globally. Each year, millions of people suffer from TB, and TB ranks
as the second leading cause of death among infectious diseases
worldwide.1 The emergence of multidrug-resistant TB (MDR-TB)
poses another challenge in the programmatic management of TB.1* Corresponding authors.
E-mail addresses: daniel.chin@gatesfoundation.org (D.P. Chin),
zhaoyanlin@chinatb.org (Y. Zhao).
http://dx.doi.org/10.1016/j.ijid.2014.09.011
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).China has the second highest TB burden and the greatest number of
MDR-TB cases in the world.2 According to the National Anti-
Tuberculosis Drug Resistance Survey in 2007,3 approximately
12 000 new MDR-TB cases emerge annually in China, accounting
for 24% of MDR-TB cases worldwide.2 Although MDR-TB represents
only 8% of incident TB cases in China, controlling MDR-TB remains
a great challenge due to the difﬁculties in diagnosis and treatment.
A lack of laboratory capacity and delays in obtaining test results in
resource-limited settings are also barriers to MDR-TB control.4,5
The Xpert MTB/RIF assay (referred to as MTB/RIF in this article)
is an in vitro diagnostic technology of semi-nested, real-time
ﬂuorescent quantitative PCR that targets the 81-bp rifampinciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
X. Ou et al. / International Journal of Infectious Diseases 31 (2015) 41–4642resistance-determining region of the rpoB gene. MTB/RIF detects
Mycobacterium tuberculosis (MTB) and rifampin resistance simul-
taneously.6–10 The MTB/RIF assay has shown excellent perfor-
mance in multicenter studies undertaken in reference laboratories
and in district and sub-district health facilities in resource-poor
countries.11,12 Furthermore, the MTB/RIF assay has been endorsed
by the World Health Organization (WHO) as a promising new rapid
diagnostic technology that has the potential for large-scale roll-
out.13 However, evaluation of MTB/RIF has never been conducted
in China.
We conducted a multicenter feasibility study across four sites in
China with the aim of assessing the performance of the MTB/RIF
assay in the detection of MTB and rifampin resistance.
2. Methods
2.1. Study population
From April 2011 to January 2012, suspected non-MDR-TB
patients (persons with a cough and expectoration, or hemoptysis
for more than 2 weeks) and suspected MDR-TB patients (TB
patients with a history of relapse, return after default, initial
treatment failure, or retreatment failure) were enrolled consecu-
tively at four county-level TB laboratories in both southern
and northern China (Xiangtan and Yueyang counties in
Hunan Province, and Beilin and Lanxi counties in Heilongjiang
Province).
2.2. Sample processing
Three sputum samples (spot, night, and morning sputum) were
collected from each patient. The specimens were examined by
acid-fast bacillus (AFB) smear microscopy, solid Lo¨wenstein–
Jensen culture, and MTB/RIF test simultaneously.
Direct smear microscopy of each sputum specimen was
performed using Ziehl–Neelsen staining in accordance with the
China NTP-Sputum Smear standard procedures and Quality
Assurance Manual.14 Sputum specimens were processed for solid
culture and inoculated onto Lo¨wenstein–Jensen medium following
WHO guidelines.15 One milliliter of raw sputum was collected by
pipette and tested using the MTB/RIF assay according to the
manufacturer’s protocol.8
All culture-positive strains were transported to provincial TB
reference laboratories for conventional drug susceptibility testing
(DST) of rifampin and isoniazid as per the WHO guidelines,15 using
40 mg/ml rifampin and 0.2 mg/ml isoniazid.
The China National TB Reference Laboratory (NTRL) collected all
strains to perform 16S–23S rDNA internal transcribed spacer (ITS)
sequencing for species identiﬁcation.16
Strains with discordant results between conventional DST
and the MTB/RIF assay were subjected to PCR ampliﬁcation and
DNA sequencing of the 81-bp rpoB core region with forward
(CTTGCACGAGGGTCAGACCA) and reverse (ATCTCGTCGCTAAC-
CACGCC) primers.17 The sequencing results were entered into
the Basic Local Alignment Search Tool (BLAST), an international
data bank (http://www.ncbi.nlm.nih.gov/BLAST), for comparison
with the reference strain H37Rv.
2.3. Ethical considerations
The study was approved by the Ethics Committee of the Chinese
Center for Disease Control and Prevention. Because the study was
conducted on routine samples only and did not involve any
changes in intervention, the requirement to obtain individual
informed consent was waived by the review board.2.4. Statistical analysis
Statistical analysis was performed using Microsoft Excel and
SPSS v. 15.0 (SPSS Inc., Chicago, IL, USA). A Chi-square test was
used for the statistical analysis. A p-value of less than 0.05 was
considered signiﬁcant.
3. Results
3.1. Study population
From April 2011 to January 2012, a total of 2454 suspected TB
cases (2142 suspected non-MDR-TB and 312 suspected MDR-TB)
were enrolled consecutively into this study; 1741 subjects were
male and 713 were female.
3.2. Performance analysis of the MTB/RIF assay for MTB detection in
suspected non-MDR-TB cases
In 2142 suspected non-MDR-TB cases, the rates of MTB detection
by smear microscopy, solid culture, and MTB/RIF assay were 13.3%
(284/2142), 26.9% (577/2142), and 31.9% (683/2142), respectively.
The detection rate of MTB/RIF was signiﬁcantly higher than that of
smear microscopy (Chi-square 214.68, p = 1.3  1048) and that of
solid culture (Chi-square 12.31, p = 0.000451).
Of the 2142 suspected non-MDR-TB cases enrolled in the study,
48 were excluded from analysis of the performance of the MTB/RIF
assay for MTB detection (Figure 1). For the remaining 2094 sus-
pected non-MDR-TB cases, the sensitivity and speciﬁcity of the
MTB/RIF assay for MTB detection were analyzed using solid culture
as the reference standard (Table 1). The diagnostic results of
1911 patients (91.3%) by MTB/RIF were consistent with those
obtained by solid culture. A total of 519 out of 550 culture-positive
patients were detected positive by the MTB/RIF assay resulting in a
sensitivity of 94.4%, while 1392 out of 1544 culture-negative
patients were detected negative by the MTB/RIF assay resulting in
a speciﬁcity of 90.2%; the positive predictive value (PPV) and
negative predictive value (NPV) of the MTB/RIF assay for MTB
detection were 77.4% and 97.8%, respectively.
3.3. Performance analysis of the MTB/RIF assay for the detection of
rifampin resistance in suspected non-MDR-TB cases
Among the 550 culture-positive suspected non-MDR-TB cases,
one failed the MTB/RIF assay and 31 tested negative for MTB by
MTB/RIF. Therefore, 518 suspected non-MDR-TB cases were used
for evaluation of MTB/RIF for the detection of rifampin resistance
(Figure 1).
For the 518 culture-positive suspected non-MDR-TB cases, the
sensitivity and speciﬁcity of the MTB/RIF test for the detection of
rifampin resistance were analyzed using conventional DST as the
reference standard. Twenty-seven out of 31 rifampin-resistant
isolates identiﬁed by DST were conﬁrmed resistant by the MTB/RIF
assay, resulting in a sensitivity of 87.1%. Out of 487 isolates that
were rifampin-sensitive TB by DST, 477 were conﬁrmed sensitive
by the MTB/RIF assay, resulting in a speciﬁcity of 97.9%. The PPV
and NPV of the MTB/RIF test for the detection of rifampin
resistance in suspected non-MDR-TB cases were 71.1% and 99.4%,
respectively (Table 2).
3.4. Performance analysis of the MTB/RIF assay for the detection of
rifampin resistance in suspected MDR-TB cases
Of the 312 suspected MDR-TB cases enrolled in this study, four
were excluded for the analysis of the performance of the MTB/RIF
assay for the detection of rifampin resistance due to culture
2454 eligible patients (2142
non MDR-TB suspects and
312 MDR-TB suspects)
31 RIF
resistant
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11 Xpert MTB detection Failure
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Figure 1. Flow chart of case inclusion and detection.
Table 1
Diagnostic performance of the MTB/RIF for the detection of MTB in suspected non-MDR-TB cases
Site and number of tests Sensitivity Speciﬁcity
(No tuberculosis)
PPV NPV
All culture-positive Smear-negative,
culture-positive
Suspected non-MDR-TB
Xiangtan
Correct No./total No. (%) 196/208 (94.2%) 83/95 (87.4%) 269/297 (90.6%) 196/224 (87.5%) 269/281 (95.7%)
95% CI (91.1–97.4) (80.7–94.1) (87.3–93.9) (83.2–91.8) (93.4–98.1)
Yueyang
Correct No./total No. (%) 106/113 (93.8%) 58/65 (89.2%) 464/526 (88.2%) 106/168 (63.1%) 464/471 (98.5%)
95% CI (89.4–98.3) (81.7–96.8) (85.5–91.0) (55.8–70.4) (97.4–99.6)
Beilin
Correct No./total No. (%) 152/160 (95.0%) 75/83 (90.4%) 286/312 (91.7%) 152/178 (85.4%) 286/294 (97.3%)
95% CI (91.6–98.4) (84.0–96.7) (88.6–94.7) (80.2–90.6) (95.4–99.1)
Lanxi
Correct No./total No. (%) 65/69 (94.2%) 30/34 (88.2%) 373/409 (91.2%) 65/101 (46.2%) 373/377 (98.9%)
95% CI (88.0–99.7) (77.4–99.1) (88.5–93.9) (55.0–73.7) (97.8–100.0)
All patients
Correct No./total No. (%) 519/550 (94.4%) 246/277 (88.8%) 1392/1544 (90.2%) 519/671 (77.4%) 1392/1423 (97.8%)
95% CI (92.4–96.3) (85.1–92.5) (88.7–91.6) (74.2–80.5) (97.1–98.6)
MTB, Mycobacterium tuberculosis; MDR-TB, multidrug-resistant tuberculosis; PPV, positive predictive value; NPV, negative predictive value; CI, conﬁdence interval.
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Table 2
Diagnostic performance of the MTB/RIF for the detection of rifampin resistance in suspected non-MDR-TB cases and MDR-TB cases
Site and number of tests Sensitivity Speciﬁcity PPV NPV
Suspected non-MDR-TB
Xiangtan
Correct No./total No. (%) 5/5 (100.0%) 189/191 (99.0%) 5/7 (71.4%) 189/189 (100.0%)
95% CI (47.8–100.0) (97.5–100.0) (38.0–100.0) (98.2–100.0)
Yueyang
Correct No./total No. (%) 8/9 (88.9%) 93/97 (95.9%) 8/12 (66.7%) 93/94 (98.9%)
95% CI (68.4–100.0) (91.9–99.8) (40.0–93.3) (96.9–100.0)
Beilin
Correct No./total No. (%) 7/8 (87.5%) 140/144 (97.2%) 7/11 (58.3%) 140/141 (99.3%)
95% CI (64.6–100.0) (94.5–99.9) (30.4–86.2) (94.6–100.0)
Lanxi
Correct No./total No. (%) 7/9 (77.8%) 55/55 (100.0%) 7/7 (100.0%) 55/57 (96.5%)
95% CI (50.6–100.0) (94.0–100.0) (59.0–100.0) (91.7–100.0)
All patients
Correct No./total No. (%) 27/31 (87.1%) 477/487 (97.9%) 27/37 (71.1%) 477/481 (99.4%)
95% CI (75.3–98.9) (96.7–99.2) (56.6–85.5) (98.7–100.0)
Suspected MDR-TB
Xiangtan
Correct No./total No. (%) 6/6 (100.0%) 25/25 (100.0%) 6/6 (100.0%) 25/25 (100.0%)
95% CI (54.1–100.0) (85.8–100.0) (54.1–100.0) (85.8–100.0)
Yueyang
Correct No./total No. (%) 8/9 (88.9%) 2/2 (100.0%) 8/8 (100.0%) 2/3 (66.7%)
95% CI (68.4–100.0) (15.8–100.0) (63.1–100.0) (13.3–100.0)
Beilin
Correct No./total No. (%) 7/8 (87.5%) 29/34 (85.3%) 7/12 (58.3%) 29/30 (96.7%)
95% CI (64.6–100.0) (73.4–97.2) (30.4–86.2) (90.2–100.0)
Lanxi
Correct No./total No. (%) 6/8 (75.0%) 5/6 (83.3%) 6/7 (85.7%) 5/7 (71.4%)
95% CI (45.0–100.0) (53.5–100.0) (59.8–100.0) (38.0–100.0)
All patients
Correct No./total No. (%) 27/31 (87.1%) 61/67 (91.0%) 27/33 (81.8%) 61/65 (93.9%)
95% CI (75.3–98.9) (84.2–97.9) (68.7–95.0) (88.0–99.7)
MDR-TB, multidrug-resistant tuberculosis; PPV, positive predictive value; NPV, negative predictive value; CI, conﬁdence interval.
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for evaluation of the MTB/RIF assay (Figure 1).
MTB was detected by culture for 101 of the 298 suspected MDR-
TB cases. Of these 101 isolates, one failed the MTB/RIF assay and
two tested negative for MTB by the MTB/RIF assay. Therefore,
98 MDR-TB patients were available to evaluate the performance of
the MTB/RIF assay for the detection of rifampin resistance
(Figure 1).
The MTB/RIF assay correctly identiﬁed 27 of 31 suspected MDR-
TB cases (87.1%) with rifampin-resistant TB detected by conven-
tional DST, and 61 of 67 suspected MDR-TB cases (91.0%) with
rifampin-sensitive TB detected by conventional DST. The PPV and
NPV of MTB/RIF for the detection of rifampin resistance in
suspected MDR-TB cases were 81.8% and 93.9%, respectively
(Table 2).
3.5. Sequencing analysis of discrepant cases of rifampin resistance
For 24 cases with discordant rifampin resistance results
between conventional DST and MTB/RIF, the rpoB gene was
sequenced to conﬁrm rifampin resistance. Of the 16 false-positive
cases, 11 contained mutations as identiﬁed by MTB/RIF, while no
mutation was found in the other ﬁve cases. Mutations at codon
511 were found in seven cases, codon 531 in three cases, and codon
526 in one case. In addition, we found mutations in all of the eight
false-negative cases, including mutations at codon 533 in three
cases, codon 522 in three cases, codon 516 in one case, and codon
526 in one case. Taking the sequencing results into account, the
sensitivities for rifampin resistance were recalculated as 88.9% in
suspected non-MDR-TB cases and 89.2% in suspected MDR-TB
cases, respectively. The PPV increased from 71.1% to 86.5% in
suspected non-MDR-TB cases and increased from 81.8% to 100% in
suspected MDR-TB cases.3.6. Impact of multiple sputum specimens on the performance of MTB/
RIF
The sensitivities of the MTB/RIF assay for MTB detection when
using one sputum sample (spot sputum, night sputum, or morning
sputum), two sputum samples (spot/night, spot/morning, or night/
morning), or three sputum samples (spot/night/morning) were
calculated and compared to each other (Table 3). The statistical
analysis showed that different sputum combinations had no effect
on the performance of the MTB/RIF for MTB detection. Comparing
the sensitivities of MTB/RIF for MTB detection using one sample of
spot sputum, two samples (morning and night sputa), and three
samples (spot, morning, and night), showed no statistically
signiﬁcant difference in detection based on the number of sputum
samples tested (one sputum/two sputa p = 0.74; one sputum/three
sputa p = 0.354; two sputa/three sputa p = 0.542). Therefore,
increasing the specimen number does not appear to increase
the sensitivity of MTB/RIF for MTB detection.
3.7. Indeterminate results of the MTB/RIF test
The MTB/RIF assay provides an indeterminate result if
unexpected results occur with any of the internal control
measurements. The MTB/RIF indeterminate rate was 9.2% (727/
7935) including repeat tests, which was higher than the rate of
culture contamination (4.7%). Among the 727 indeterminate tests,
further analysis showed that invalid, error, and no results
accounted for 26.9% (196/727), 55.6% (404/727), and 17.5%
(127/727), respectively. Among 2059 samples in which M.
tuberculosis was detected by MTB/RIF, 20 (0.97%) specimens
yielded indeterminate results for rifampin resistance. Of
these, all were smear-negative, eight were culture-positive, and
12 were culture-negative. Nineteen showed very low detection
Table 3
Inﬂuence of multiple sputum specimens on the performance of the MTB/RIF test
Samples Sensitivity Speciﬁcity PPV NPV
3 Sputa (spot, morning, and night sputum)
Correct No./total No. (%) 484/515 (94.0%) 1392/1543 (90.2%) 484/635 (76.2%) 1392/1423 (97.8%)
95% CI (91.9–96.0) (88.7–91.7) (72.9–79.5) (97.1–98.6)
2 Sputa (spot and night sputum)
Correct No./total No. (%) 483/517 (93.4%) 1413/1571 (89.9%) 483/641 (75.4%) 1413/1447 (97.7%)
95% CI (91.3–95.6) (88.5–91.4) (72.0–78.7) (96.9–98.4)
2 Sputa (spot and morning sputum)
Correct No./total No. (%) 7/8 (94.9%) 140/144 (91.3%) 7/11 (79.0%) 140/141 (98.1%)
95% CI (93.1–96.8) (89.9–92.7) (75.8–82.1) (97.4–98.8)
2 Sputa (night and morning sputum)
Correct No./total No. (%) 487/521 (93.5%) 1407/1530 (92.0%) 487/610 (79.8%) 1407/1441 (97.6%)
95% CI (91.4–95.6) (90.6–93.3) (76.7–83.0) (96.9–98.4)
1 Spot sputum
Correct No./total No. (%) 435/468 (93.0%) 1436/1563 (91.9%) 435/562 (77.4%) 1436/1469 (97.8%)
95% CI (90.6–95.3) (90.5–93.2) (73.9–80.9) (97.0–98.5)
1 Night sputum
Correct No./total No. (%) 406/451 (90.0%) 1410/1538 (91.7%) 406/534 (76.0%) 1410/1455 (96.9%)
95% CI (87.3–92.8) (90.3–93.1) (72.4–79.7) (96.0–97.8)
1 Morning sputum
Correct No./total No. (%) 437/471 (92.8%) 1417/1514 (93.6%) 437/534 (81.8%) 1417/1451 (97.7%)
95% CI (90.4–95.1) (92.4–94.8) (78.6–85.1) (96.9–98.4)
PPV, positive predictive value; NPV, negative predictive value; CI, conﬁdence interval.
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MTB/RIF.
4. Discussion
MTB/RIF can be both sensitive and speciﬁc when used as an
initial diagnostic test for TB and rifampin resistance in patients
suspected of having TB, MDR-TB, or HIV-associated TB. It is also
valuable as an add-on test following microscopy for patients who
have previously been found to be smear-negative.18 By June 2012,
two thirds of the countries with a high TB burden and half of the
countries with a high MDR-TB burden had incorporated MTB/RIF
into their national tuberculosis program guidelines.19
In this study, when MTB/RIF was used to diagnose TB in
suspected non-MDR-TB cases, it showed high sensitivity and
speciﬁcity, and the PPV was lower than values reported by other
studies.20 The lower PPV might be related to the lower sensitivity
of solid culture, which was used as the gold standard in this study,
compared to liquid culture, which has commonly been used
elsewhere as the gold standard. Another reason for the lower PPV
might be related to delayed testing because of the four-module
MTB/RIF instrument, which is only capable of running 12 speci-
mens per day. In addition, the lower PPV in Yueyang and Lanxi
counties might be related to the lower local TB prevalence.
When using MTB/RIF to detect rifampin resistance in suspected
non-MDR-TB and MDR-TB cases, the PPV of MTB/RIF in suspected
non-MDR-TB cases was signiﬁcantly lower than in suspected MDR-
TB cases. This might be due to a difference in prevalence of
rifampin resistance between the two populations.21 According to
the National Survey of Drug-Resistant Tuberculosis in China,3 6.7%
of new TB cases and 29.4% of previously treated cases were
resistant to rifampin. Thus, MTB/RIF may provide a reliable method
of diagnosing rifampin resistance in suspected MDR-TB cases in
whom the prevalence of resistance might be more than 20%.
However, for suspected non-MDR-TB cases, the WHO recommends
using conventional DST to conﬁrm rifampin resistance since the
use of MTB/RIF in a population with a low prevalence of rifampin
resistance may generate high numbers of false-positive results.22
Previous reports have shown that approximately 90% of
patients with rifampin-resistant TB might also have resistance
to isoniazid, meaning that they would have MDR-TB.23–25
However, in the present study, only 31 (44.3%) MDR-TB caseswere detected among the 70 rifampin-resistant cases diagnosed by
MTB/RIF. Meanwhile, 38 (59%) MDR-TB cases were detected in
65 rifampin-resistant cases diagnosed by conventional DST. Both
ﬁgures were far below what has been reported previously. This
discrepancy might be due to the high TB burden and high
differentiation of MTB strains in China. Therefore, these results
suggest that rifampin resistance cannot be used as an indicator of
MDR-TB in China.
National guidelines have recommended obtaining three spu-
tum specimens from patients with suspected TB.26 In the present
study, we assessed the contribution of additional specimens to the
ultimate diagnosis of TB for suspected non-MDR-TB cases.
Interestingly, in our study, the sensitivity of MTB/RIF for MTB
detection in suspected non-MDR-TB cases from whom only one
specimen was analyzed did not differ signiﬁcantly from the
sensitivity achieved by testing two or three specimens. This result
indicates that the collection of one sputum specimen should be
adequate in establishing a diagnosis of TB using MTB/RIF.
In our study, the indeterminate rate of MTB/RIF was 9.2%, which
was higher than the contamination rate (4.7%) of culture. The
indeterminate rate was also higher than the 2.4% indeterminate
rate reported previously.12 This was likely due to the breakdown of
MTB/RIF instruments in Lanxi and Yueyang counties during the
study period. Other possible contributors to the high rate of
indeterminate results were PCR inhibition, poor sample proces-
sing, temperature error, probe failure, or poor storage of cartridges.
Specimens that yielded indeterminate results for rifampin resis-
tance were all smear-negative and had low detection of MTB by
MTB/RIF. Our results therefore suggest that the performance of the
MTB/RIF test for rifampin resistance was inﬂuenced by the amount
of bacteria in the sputum samples.27
Among the 16 isolates for which rifampin resistance was
detected by MTB/RIF but not by conventional DST-RIF, 11 had rpoB
mutations by sequencing, which means the traditional DST has
lower sensitivity. All eight isolates for which rifampin sensitivity
was indicated by MTB/RIF but resistance was detected by
conventional DST had rpoB mutations. This might have occurred
because the resistant bacteria in these specimens only accounted
for a small proportion of the total germ population. Five strains
were predicted to be sensitive to rifampin based on sequencing,
but had rifampin resistance detected by MTB/RIF. This may be due
to the errors in reading the MTB/RIF results.28 The software cut-off
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order to improve the speciﬁcity for the detection of rifampin
resistance. Nevertheless, there was still a certain number of false-
positives in the detection of rifampin resistance. Mutations in the
rpoB gene were found by sequencing in eight cases in which the
MTB/RIF results were sensitive; they were codon 516 which was
included in probe B mutant, codon 522 in probe C, codon 526 in
probe D, and codon 533 in probe E. In another study, Armand et al.
found that a lower concentration of MTB in the specimen may lead
to the detection of false rifampin sensitivity by MTB/RIF.29 These
issues require early resolution by reconﬁguration of the software
or redesigning of the molecular probes, in view of impending large-
scale implementation in peripheral county-level laboratories.
In conclusion, this study is the ﬁrst large-scale evaluation of
MTB/RIF in the county-level laboratory in China. In our study, the
detection rate of the MTB/RIF test was higher than solid culture,
and it was an effective alternative to conventional DST for the
detection of rifampin resistance among suspected MDR-TB cases. It
offered certain beneﬁts for county-level TB laboratories because of
the ease of use.
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